<DOC>
	<DOCNO>NCT00767689</DOCNO>
	<brief_summary>Capecitabine ( Xeloda ) drug cancer therapy . Its use limit often toxicity . This study ask vitamin B6 prevent one common toxicity xeloda numbness and/or rash hand foot , condition call Hand Foot syndrome . patient , start capecitabine chemotherapy cancer , participate study John H. Stroger Jr. Hospital Cook County . They randomize receive either vitamin B6 placebo . investigator patient blind intervention .</brief_summary>
	<brief_title>A Randomized Trial Determine Vitamin B6 Can Prevent Hand Foot Syndrome Cancer Patients Treated With Capecitabine Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Any adult patient start capecitabinecontaining chemotherapy Has never capecitabine Performance status 02 use ECOG classification Life expectancy 6 month Agreed stop vitamin supplement , apart vitamin D. Liver function study include AST/ALT within 3x upper limit normal Signed inform consent must obtain participate individual</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>